



Global Markets for Vaccine Technologies

April 2018

Anuj Pathak

Report Code: PHM041G



Table of Contents

Chapter 1: Introduction	1
Study Goals and Objectives.....	1
Reasons for Doing This Study.....	1
Scope of Report.....	2
Information Sources.....	2
Methodology.....	3
Information Sources.....	3
Geographic Breakdown.....	4
Analyst's Credentials.....	6
Related BCC Research Reports.....	6
Chapter 2: Summary and Highlights	8
Chapter 3: Market and Technology Background	11
Definitions.....	11
Immune System and Vaccines	11
How Vaccines Work.....	12
Types of Immunity.....	12
Advantages of Vaccination	13
History of Vaccines	13
Types of Vaccines	15
Adjuvants and Excipients.....	26
Infectious Diseases Preventable by Vaccines.....	33
Rapid Manufacturing for Pandemics.....	50
Laws and Regulations	55
Opportunities	63
Current Situation	64
Chapter 4: Market Breakdown by Human Vaccine	86
Types of Human Vaccines	88
Attenuated (Live) Vaccines.....	88
Inactivated Vaccines.....	89
Conjugate Vaccines	90
rDNA/DNA Vaccines	91
Subunit Vaccines	93
Toxoid Vaccines.....	94
Other/Combination Vaccines.....	95
Vaccine by Age Group	96
Vaccine by Disease Type.....	110
Chapter 5: Market Breakdown by Animal Vaccines	124
Animal Vaccines	124
Market by Type	126
Chapter 6: Patent Analysis	134
Patents by Year	134
Patents by Vaccine Type	135
Patents by Patent Office	136
Patents by Company	137

Patents by Assignee	141
Chapter 7: Market Breakdown by Region	143
North America.....	149
U.S.	149
Canada.....	153
Europe.....	155
Germany.....	155
France.....	156
U.K.	158
Italy.....	160
Rest of Europe.....	161
Asia-Pacific	163
China.....	163
Japan.....	165
India.....	167
Rest of APAC.....	169
Rest of World	169
Chapter 8: Company Profiles	173
Appendix.....	204
About BCC Research.....	212
About BCC Research.....	213
BCC Custom Research	213

List of Tables

Summary Table Global Market for Vaccine Technologies, by Segment, Through 2022 (\$ Millions).....	9
Table 1 History of Vaccines	13
Table 2 Types of Attenuated (Live) Vaccines	16
Table 3 Advantages and Disadvantages of Attenuated (Live) Vaccines	17
Table 4 Types of Inactivated (Killed) Vaccines	18
Table 5 Advantages and Disadvantages of Inactivated (Killed) Vaccines	18
Table 6 Types of Toxoid Vaccines	19
Table 7 Advantages and Disadvantages of Toxoid Vaccines.....	20
Table 8 Types of Subunit Vaccines.....	21
Table 9 Advantages and Disadvantages of Subunit Vaccines	21
Table 10 Types of Conjugate Vaccines.....	22
Table 11 Advantages and Disadvantages of Conjugate Vaccines	22
Table 12 Types of Recombinant Vector Vaccines	23
Table 13 Advantages and Disadvantages of Recombinant Vector Vaccines	23
Table 14 Types of DNA Vaccines	24
Table 15 Advantages and Disadvantages of DNA Vaccines	24
Table 16 Advantages and Disadvantages of RNA Vaccines	25
Table 17 Vaccine Excipient and Media Summary, Excipients included in U.S. Vaccines,	29
Table 18 Vaccine-Preventable Human Viral Diseases.....	34
Table 19 Vaccine-Preventable Human Bacterial Diseases.....	36
Table 20 Vaccine-Preventable Parasitic Animal Diseases Found in Food-Producing Animals	40
Table 21 Vaccine-Preventable Bacterial Animal Diseases Found in Food-producing Animals.....	40
Table 22 Vaccine-Preventable Viral Animal Diseases Found in Food-producing Animals.....	41
Table 23 Vaccine-Preventable Parasitic Animal Diseases Found in Companion Animals	42
Table 24 Vaccine-Preventable Bacterial Animal Diseases Found in Companion Animals	43
Table 25 Vaccine-Preventable Viral Animal Diseases Found in Companion Animals.....	43
Table 26 Vaccine-Preventable Viral Animal Diseases Found in Other Animals.....	44
Table 27 Animal Vaccines for Food-Producing, Companion and Other Animals.....	45
Table 28 Cases of Diphtheria, 2011-2015 (Number)	60
Table 29 WHO Prequalified Vaccines, January 2014-November 2017	71
Table 30 Newly Approved Vaccines, January 2014-November 2017	76
Table 31 Global Vaccine Recalls, January 2014-November 2017	77
Table 32 Global Vaccine Shortage, January 2012-November 2017	78
Table 33 Human Vaccines in Research Pipeline, as of November 2017	80
Table 34 Alliances and Joint Ventures for the Development of Human and Animal Vaccines, January 2014-November 2017	82
Table 35 Recent Vaccine Product launches, January 2014-November 2017.....	84
Table 36 Global Market for Human Vaccines, by Type, Through 2022 (\$ Millions)	87
Table 37 Global Market for Attenuated (Live) Vaccine, by Region, Through 2022 (\$ Millions)	89
Table 38 Global Market for Inactivated (Killed) Vaccines, by Region, Through 2022 (\$ Millions)	90
Table 39 Global Market for Conjugate Vaccines, by Region, Through 2022 (\$ Millions)	91
Table 40 Global Market for Recombinant/rDNA/DNA Vaccines, by Region, Through 2022 (\$ Millions) ...	93
Table 41 Global Market for Subunit Vaccines, by Region, Through 2022 (\$ Millions)	94
Table 42 Global Market for Toxoid Vaccines, by Region, Through 2022 (\$ Millions).....	95
Table 43 Global Market for Other/Combination Vaccines, by Region, Through 2022 (\$ Millions).....	96
Table 44 Global Market for Human Vaccines, by Age Group, Through 2022 (\$ Millions).....	96
Table 45 Pediatric Vaccines Doses	97

Table 46 Pediatric/VFC Vaccine Price List, 2017	100
Table 47 Pediatric Influenza Vaccine Price List	102
Table 48 Vaccines Dose by Age	104
Table 49 Global Market for Human Vaccines for Pediatrics, by Region, Through 2022 (\$ Millions).....	105
Table 50 Global Market for Human Vaccines for Adults, by Region, Through 2022 (\$ Millions)	106
Table 51 Adult Vaccine Price List	107
Table 52 Vaccine Price List for Geriatric Population (\$)	109
Table 53 Global Market for Human Vaccines for Geriatrics, by Region, Through 2022 (\$ Millions).....	109
Table 54 Vaccines, by Disease Type	111
Table 55 Seasonal Influenza Vaccines.....	112
Table 56 Site by Age for Intramuscular Immunization	116
Table 57 Nasal Vaccines	117
Table 58 Vaccines by Route of Delivery	118
Table 59 Global Market for Human Vaccines, by Disease Type, Through 2022 (\$ Millions)	119
Table 60 Global Market for Meningococcal/Pneumococcal Vaccines, by Region, Through 2022 (\$ Millions)	120
Table 61 Global Market for Influenza Vaccines, by Region, Through 2022 (\$ Millions).....	120
Table 62 Global Market for Pediatric Polio/Pertussis/Hib Vaccines, by Region, Through 2022 (\$ Millions)	120
Table 63 Global Market for Endemic Diseases Vaccines, by Region, Through 2022 (\$ Millions).....	121
Table 64 Global Market for HPV Vaccines, by Region, Through 2022 (\$ Millions).....	121
Table 65 Global Market for Rotavirus Vaccines, by Region, Through 2022 (\$ Millions)	121
Table 66 Global Market for Vaccines for Other Diseases, by Region, Through 2022 (\$ Millions).....	122
Table 67 Global Market for Animal Vaccines, by Type, Through 2022 (\$ Millions).....	126
Table 68 Global Market for Vaccines for Food-Producing Animals, by Region, Through 2022 (\$ Millions)	129
Table 69 Global Market for Vaccines for Companion Animals, by Region, Through 2022 (\$ Millions)....	131
Table 70 Global Market for other Animal Vaccines, by Region, Through 2022 (\$ Millions).....	132
Table 71 U.S. Patents Issued for Vaccines, by Year, January 2015-November 2017 (Number of Patents)	134
Table 72 U.S. Patents by Type of Vaccine, January 2015-November 2017 (Number of Patents)	135
Table 73 Patents by Vaccine Type, January 2014-September 2016 (Number of Patents)	136
Table 74 Patents by Company, January 2015-November 2017 (Number of Patents).....	137
Table 75 U.S. Patents by Assignee Type, January 2015-November 2017 (Number of Patents).....	141
Table 76 UNICEF Vaccination Price and Major Suppliers, 2017.....	145
Table 77 Estimated Life Saved due to Vaccination, 2011-2020 (Assuming No Vaccination as the Counterfactual) (Millions).....	149
Table 78 U.S. Recommended Immunization Schedule, by Vaccine Type, 2017	151
Table 79 Vaccine Price List, 2017 (\$).....	152
Table 80 Immunization Schedule of Germany, 2016.....	153
Table 81 Immunization Schedule of Germany, 2016.....	155
Table 82 Immunization Schedule of France, 2016.....	157
Table 83 Vaccination and Immunization Schedule of China, 2016.....	159
Table 84 Immunization Schedule of Italy, 2016.....	161
Table 85 Immunization Schedule of China, 2016.....	164
Table 86 Immunization Schedule of Japan, 2016	166
Table 87 Immunization Schedule of India, 2016.....	167
Table 88 Number of Reported Cases in India, 2013-2016	168
Table 89 GAVI Support to India, 2001-2021 (\$ Millions)	168
Table 90 Africa WHO/ UNICEF Vaccination Coverage Estimate, 2005-2016 (%).....	170
Table 91 Middle East WHO/ UNICEF Vaccination Coverage Estimate, 2005-2016 (%)	171

Table 92 Patents Taken into Consideration for this Report..... 204

List of Figures

Summary Figure Global Market for Vaccine Technologies, by Segment, 2016-2022 (\$ Millions).....	9
Figure 1 Population Percent that can Read and Write Above the Age of 15, 2015 (%)	62
Figure 2 Infants Lacking Immunization Measles, 2014 (% of One-Year-Olds)	63
Figure 3 Polio Cases in the U.S., 1950-2015 (First Vaccine Licensed in 1955)	98
Figure 4 Percent of Children Aged 19-35 Months Receiving Vaccinations in the U.S., 2015 (%)	99
Figure 5 Immunization Coverage Globally, 2016 (%).....	99
Figure 6 Seasonal Flu Vaccination Coverage in the U.S., 2013-2017 (% of Children Ages 6 Months-17 Years)	102
Figure 7 Immunization Globally, 2013-2016 (% of Children Aged 12-23 Months)	103
Figure 8 Diphtheria Cases in the U.S., 1945-2015 (Vaccine Licensed in 1947).....	106
Figure 9 Seasonal Flu Vaccination Coverage in the U.S., 2013-2017 (% of Adults Older Than 18 Years of Age)	108
Figure 10 WHO/UNICEF Vaccine Coverage Estimate, 2015-2016 (%)	110
Figure 11 Hepatitis A Cases in the U.S., 1990-2014 (First Vaccine Licensed in 1995)	112
Figure 12 Measles Cases in the U.S., 1960-2014 (Vaccine Licensed in 1963).....	113
Figure 13 Chickenpox Cases in the U.S., 1975-2014 (Vaccine Licensed in 1995)	114
Figure 14 U.S. Patents Issued for Vaccines, by Year, January 2015-November 2017 (Number of Patents)	135
Figure 15 U.S. Patents, by Type of Vaccine, January 2015-November 2017 (Number of Patents)	136
Figure 16 Global Immunization Coverage, 2016 (%).....	143
Figure 17 Donor Contributions to GAVI Alliance, 2000-2020 (%)	144
Figure 18 Global Investment in R&D Vaccination, 2012-2015 (\$ Millions).....	148
Figure 19 Donation from the U.S. to GAVI, 2013-2016 (\$ Millions)	150
Figure 20 Canada Cash Funding to GAVI, 2013-2016 (\$ Millions)	154
Figure 21 Germany Funding to GAVI, 2013-2016 (\$ Millions)	156
Figure 22 France Funding to GAVI, 2012-2015 (\$ Millions)	158
Figure 23 U.K. Funding to GAVI, 2013-2016 (\$ Millions)	160
Figure 24 Donation of European Governments and Organizations to Gavi, 2013-2016 (\$ Millions).....	162
Figure 25 Investment by APAC Counties in Vaccination R&D, 2012-2015 (\$ Millions)	163
Figure 26 China Support to GAVI, 2001-2021 (%).....	165
Figure 27 Japan Funding to Gavi, 2011-2020 (\$ Millions).....	166
Figure 28 Australia Funding to GAVI, 2013-2016 (\$ Millions).....	169



About BCC Research

About BCC Research

With our unparalleled 45-year history, BCC Research provides comprehensive analyses of global market sizing, forecasting and industry intelligence, covering markets where advances in science and technology are improving the quality, standard and sustainability of businesses, economies and lives.

BCC Membership

From market sizing and forecasts, to opportunity assessments and competitive analyses, our ever-expanding library gives you the data, insights and intelligence required to ensure your project is a success. Members benefit from ongoing, unlimited access to the category or collections of their choice, and most membership packages pay for themselves within two to three reports being accessed.

Did you buy this report? You may qualify to apply your purchase price toward a full membership. Call 866-285-7215 or e-mail info@bccresearch.com to request a demo.

BCC Custom Research

Our experts provide custom research projects to those working to identify new markets, introduce new products, validate existing market share, analyze competition and assess the potential for products to impact existing markets. With impressive academic credentials and broad and deep knowledge of global industrial markets, our independent analysts and consultants develop the facts, figures, analysis and assessments to inform the decisions that will move your company ahead. Confidential inquiries to: custom@bccresearch.com or 781-205-2429.

DISCLAIMER

The information developed in this report is intended to be as reliable as possible at the time of publication and is of a professional nature. This information does not constitute managerial, legal or accounting advice, nor should it be considered as a corporate policy guide, laboratory manual or an endorsement of any product, as much of the information is speculative in nature. BCC Research and the author assume no responsibility for any loss or damage that might result from reliance on the reported information or from its use.

ISBN: 978-1-62296-666-0
April 2018